GlobeNewsWire
15 May 2026, 11:35 UTC · 24w ago
Verdict
Headline takes no side. We score IMRX +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 71% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
A third-line pancreatic cancer patient receiving atebimetinib monotherapy has achieved 27 months progression-free survival to date with an ongoing 85% reduction in tumor burden.
More positive than 99% of claims this week
New survival data from the Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer will be presented in an oral session at the 2026 ASCO Annual Meeting.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 98% of claims this week
The pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer is recruiting, with first patient dosing on track for mid-2026.
More positive than 98% of claims this week
Immuneering ended Q1 2026 with $198.6 million in cash and marketable securities, providing an anticipated runway into 2029.
So whatA cash runway extending into 2029 removes near-term financing dilution risk and fully funds the company through critical Phase 3 readouts.
More positive than 92% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
The company reported positive clinical trial progress, an upcoming presentation of survival data at ASCO, and a strong cash runway into 2029.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
−28.4%
Price is moving against the score
$3.68 vs $5.14 close before publication (May 14) · not market-adjusted
IMRX chart →
